Hepion Pharmaceuticals In... (HEPA)
0.80
-0.03 (-3.50%)
At close: Mar 21, 2025, 3:59 PM
0.78
-2.10%
After-hours: Mar 21, 2025, 07:03 PM EDT
-3.50% (1D)
Bid | 0.76 |
Market Cap | 863.03K |
Revenue (ttm) | 3.47K |
Net Income (ttm) | -717.71K |
EPS (ttm) | -220 |
PE Ratio (ttm) | n/a |
Forward PE | -0.02 |
Analyst | n/a |
Ask | 0.79 |
Volume | 2,731,559 |
Avg. Volume (20D) | 876,533 |
Open | 0.78 |
Previous Close | 0.83 |
Day's Range | 0.72 - 0.83 |
52-Week Range | 0.67 - 145.00 |
Beta | 1.63 |
About HEPA
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2014
Employees 22
Stock Exchange NASDAQ
Ticker Symbol HEPA
Website https://www.hepionpharma.com
1 week ago
-39.15%
Hepion Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
1 month ago
-58.05%
Hepion Pharmaceuticals shares are trading lower after the company announced a $9 million public offering.